Business
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services,
About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California.Effective August 1, 2023, Blue Shield of California has agreed to provide commercial coverage of RaDaR across all indications for plan members, representing approximately 4.7 million covered lives. The policy considers the test medically necessary for patients with stage I-IV cancer after surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression.NeoGenomics' tumor informed RaDaR assay has been designed to detect extremely low levels of circulating tumor DNA (ctDNA) in the blood with exceptional sensitivity and specificity. RaDaR can monitor up to 48 tumor-specific variants unique to each patient's tumor giving patients additional time and information for important treatment management decisions.\"We are very pleased to achieve our first commercial coverage policy for the RaDaR minimal/molecular residual disease assay because it increases patient access to MRD testing which ultimately improves cancer patient outcomes,\" said Chris Smith, Chief Executive Officer of NeoGenomics. \"The clinical evidence generated to date, along with this commercial coverage, highlight the medical necessity of MRD testing with RaDaR to allow patients and their clinicians to make informed treatment decisions.\"For more information, visit finditwithradar.comAbout RaDaR®The RaDaR assay is a personalized, tumor-informed, highly sensitive technology that tracks a set of up to 48 tumor-specific variants in cell-free DNA (cfDNA) within a cancer patient's blood plasma. Built on the proven InVision® platform, the personalized RaDaR assay has been designed to detect minimal residual disease (MRD) and recurrence following curative intent or definitive treatment, and early signs of relapse, and has been validated for clinical use in breast, colorectal, head and neck, as well as lung cancers. MRD is the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment.The RaDaR workflow leverages proprietary algorithms ...